Severe exacerbation of psoriasis after intravenous immunoglobulin in patient with multiple sclerosis that started during biologic therapy
Abstract
Psoriasis is well known to be worsened or triggered by a number of endogenous and exogenous factors, e.g. stress, infection and drugs. These include modern biological treatment modalities that interfere with complex immunological cycles in human body such as interferon-beta or TNFa inhibitors in the management of neurological, rheumatological, gastrointestinal or paradoxically dermatological diseases.1 Likewise, systemic treatments of severe psoriasis can often trigger various comorbidities and complications.
Those facts bring challenging demands to every dermatologist and often require profound interdisciplinary cooperation. We present a case of a 30-year-old male with severe treatment- resistant erythrodermic psoriasis that first manifested at the age of 21.